Mostrar el registro sencillo del ítem
Uso de Levosimendán en el postoperatorio de cirugía cardiaca.
dc.contributor.advisor | Buitrago Bernal, Ricardo Antonio | |
dc.contributor.author | Hernández Parra, Ángela | |
dc.date.accessioned | 2013-05-23T20:13:53Z | |
dc.date.available | 2013-05-23T20:13:53Z | |
dc.date.created | 2010 | |
dc.date.issued | 2010 | |
dc.identifier.citation | . Gillies M., Bellomo R, et al. Bench-to-bedside review: Inotropic drug therapy after adult cardiac surgery – a systematic literature review. Crit Care. 2005 Jun;9(3):266- 79 | |
dc.identifier.citation | Papp Z., Csapó K., et al. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovasc Drug Rev. 2005 Spring; 23(1):71-98. | |
dc.identifier.citation | Nieminen MS, Böhm M, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Herat Failure of the Eur Heart J. 2008; 29: 2388 - 442 | |
dc.identifier.citation | Raja S., Rayen B. Levosimendan in Cardiac Surgery: Current Best: Available Evidence. Ann Thorac Surg. 2006 Apr; 81(4):1536-46. | |
dc.identifier.citation | Salmenperä M, Eriksson H., et al. Levosimendan in perioperative and critical care patients. Curr Opin Anaesthesiol. 2009 Aug; 22(4):496-501. | |
dc.identifier.citation | Opie L. Braunwald Heart Disease Cardiovascular. 8a Edición, 2007. Capítulo 21: Mecanismos de la contracción y la relajación cardiaca | |
dc.identifier.citation | Cardiovascular Physiology. Lange. 5a Edición, 2005. Capítulo 2: Características de las células musculares cardiacas | |
dc.identifier.citation | Butler J, Giamouzis G, et al. A struggle to SURVIVE: to abandon or not to abandon levosimendan? Cardiovasc Drugs Ther 2007 Oct;21(5):401-2. | |
dc.identifier.citation | Archan S, Toller W, et al. Levosimendan: current status and future prospects. Curr Opin Anaesthesiol 2008 Feb;21(1):78-84. | |
dc.identifier.citation | Delaney A, Bradford C, et al. Levosimendan for the treatment of acute severe heart failure: A meta-analysis of randomised controlled trials. Int J Cardiol. 2010 Feb 4;138(3):281-9 | |
dc.identifier.citation | Rehberg S, Ertmer C, et al. Role of Levosimendan in intensive care treatment of myocardial insufficiency. Anaesthesist 2007 Jan;56(1):30-43. | |
dc.identifier.citation | Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology 2006 Mar;104(3):556-69. | |
dc.identifier.citation | Yildiz O. Vasodilating mechanisms of levosimendan: involvement of K+ channels. J Pharmacol Sci 2007 May;104(1):1-5. | |
dc.identifier.citation | Soedeing P. Inoprotection: the perioperative role of levosimendan. Anesth Intensive Care. 2007 Dec; 35(6):845-62. | |
dc.identifier.citation | Álvarez J., Taboada M., et al. Efectos hemodinámicos del levosimendan en el postoperatorio de pacientes sometidos a cirugía cardiaca. Rev Esp Anestesiol Reanim. 2005; 52: 389-94 | |
dc.identifier.citation | Duygu H, Ozerkan F, et al. Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure. Int J Clin Pract 2008 Feb;62(2):228-33. | |
dc.identifier.citation | Delle Karth G, Buberl A, et al. Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anaesthesiol Scand 2003 Nov;47(10):1251-6. | |
dc.identifier.citation | Russ MA, Prondzinsky R, et al. Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med 2007 Dec;35(12):2732-9. | |
dc.identifier.citation | Pinto, B., Rehberg S., et al. Role of levosimendan in sepsis and septic shock. Curr Opin Anesthesiol 2008 Apr;21(2):168-77. | |
dc.identifier.citation | Tritapepe L, De Santis V, et al. Preconditioning effects of levosimendan in coronary artery bypass grafting--a pilot study. Br J Anaesth 2006 Jun;96(6):694-700 | |
dc.identifier.citation | De Hert SG, Lorsomradee S, et al. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg 2007 Apr;104(4):766-73. | |
dc.identifier.citation | Tasouli A, Papadopoulos K, et al. Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: importance of early use. Eur J Cardiothorac Surg 2007 Oct;32(4):629-33. | |
dc.identifier.citation | Levin R., Degrange M. The Calcium Sensitizer Levosimendan Gives Superior Results to Dobutamine in Postoperative Low Cardiac Output Syndrome. Rev Esp Cardiol 2008 May;61(5):471-9. | |
dc.identifier.citation | Kerbaul F, Rondelet B, et al. Effects of levosimendan versus dobutamine on pressure load-induced right ventricular failure. Crit Care Med 2006 Nov;34(11):2814-9. | |
dc.identifier.citation | Follath F, Cleland JG., et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart f Lancet 2002, Jul; 360(9328):196-202. | |
dc.identifier.citation | Moiseyev VS, Poder P., et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002 Sep;23(18):1422-32. | |
dc.identifier.citation | Johansson S, et al. Effect of levosimendan treatment on length of hospital and intensive care stay in the REVIVE I study. Crit Care 2004; 8 Sup 1: 88. | |
dc.identifier.citation | Landoni G. et al. Reducing mortality in cardiac surgery with Levosimendan: A Meta-analysis of Randomized Controlled Trials. J Cardiothorac Vasc Anesth. 2010 Feb;24(1):51-7. | |
dc.identifier.citation | Aksun N, Karahan M. et al. Timing of levosimendan in cardiac surgery. Anadolu Kardiyol Derg. 2009 Jun;9(3):223-30. | |
dc.identifier.citation | De Santis V., Vitale D. et al. Levosimendan and cardiac surgery. Cardiothorac Vasc Anesth. 2010 Feb;24(1):210. | |
dc.identifier.citation | Nieminen MS, Pollesello P, et al. Effects of levosimendan on the energy balance: preclinical and clinical evidence. J Cardiovasc Pharmacol. 2009 Apr; 53(4):302-10. | |
dc.identifier.uri | http://hdl.handle.net/10818/7516 | |
dc.description | 48 Páginas. | |
dc.description.abstract | Levosimendán es inotrópico y vasodilatador, con mecanismo de acción diferente, utilizado en falla cardiaca. En cirugía cardiaca la literatura es limitada, sin concluir efectividad e impacto en morbimortalidad. Este trabajo muestra el comportamiento hemodinámico y de perfusión tisular de pacientes con disfunción ventricular en postoperatorio, usando Levosimendán. 78 pacientes recibieron infusión de 0.1 mcg/kg/min; se recolectaron parámetros hemodinámicos y de perfusión tisular antes, durante y al finalizar la infusión para análisis descriptivo. Se observó aumento en índice cardiaco, disminución en presión capilar pulmonar; aumento en saturación venosa de oxígeno, disminución en Da-vO2, delta de CO2, tasa de extracción y base exceso. En este grupo de pacientes se observó mejoría en perfil hemodinámico y perfusión tisular, tras la infusión. | es_CO |
dc.language.iso | spa | es_CO |
dc.publisher | Universidad de La Sabana | |
dc.source | Universidad de La Sabana | |
dc.source | Intellectum Repositorio Universidad de La Sabana | |
dc.subject | Corazón | es_CO |
dc.subject | Medicamentos | es_CO |
dc.title | Uso de Levosimendán en el postoperatorio de cirugía cardiaca. | es_CO |
dc.type | bachelorThesis | |
dc.publisher.program | Especialización en Medicina Crítica y Cuidado Intensivo | |
dc.publisher.department | Facultad de Medicina | |
dc.identifier.local | 129265 | |
dc.identifier.local | TE01309 | |
dc.type.local | Tesis de especialización | |
dc.type.hasVersion | publishedVersion | |
dc.rights.accessRights | openAccess | |
dc.creator.degree | Especialista en Medicina Crítica y Cuidado Intensivo |